创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology: What are the features and advantages of the ADCC platform?

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-06-07 13:39
  • Views:

(Summary description)In today's era of rapid development of biotechnology, InnoModels' ADCC platform is leading a new era of drug development and clinical treatment with its unique features and advantages. The platform not only has a diversified experimental service system, but also focuses on simulating the in vivo environment to provide researchers with accurate and reliable data support. In the following, we will introduce the features of InnoModels' ADCC platform in detail.

InnoModels Biotechnology: What are the features and advantages of the ADCC platform?

(Summary description)In today's era of rapid development of biotechnology, InnoModels' ADCC platform is leading a new era of drug development and clinical treatment with its unique features and advantages. The platform not only has a diversified experimental service system, but also focuses on simulating the in vivo environment to provide researchers with accurate and reliable data support. In the following, we will introduce the features of InnoModels' ADCC platform in detail.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-06-07 13:39
  • Views:
Information

In today's era of rapid development of biotechnology, InnoModels' ADCC platform is leading a new era of drug development and clinical treatment with its unique features and advantages. The platform not only has a diversified experimental service system, but also focuses on simulating the in vivo environment to provide researchers with accurate and reliable data support. In the following, we will introduce the features of InnoModels' ADCC platform in detail.
First of all, the ADCC platform of InnoModels Biotechnology has a diversified experimental service system. It supports a variety of tumor cell and immune cell combination experiments, whether it is tumor cell lines, primary tumor cells or genetically engineered cell lines, the platform can provide the appropriate experimental conditions and technical support. This diversified experimental system allows researchers to select the most suitable cell types according to specific research needs, thus more accurately simulating biological processes in vivo.
Secondly, the platform focuses on simulating the in vivo environment to more realistically reflect the actual situation of the ADCC process. In terms of experimental design, the InnoModels Biotechnology ADCC platform utilizes advanced cell culture technology and flow cytometry. These technologies are able to monitor and record the changes of cells in real-time during the experiment, effectively differentiate effective target cells, count and calculate the proportion of apoptotic cells. In this way, researchers can gain a deeper understanding of the mechanism of the ADCC process, providing powerful support for drug development and clinical treatment.

 


In addition, the InnoModels ADCC platform has highly consistent primary cells. Utilizing the digestion products of the PDX model, the platform is able to obtain primary cells that are highly consistent with patients. Such cells have complex cellular subpopulations and biological characteristics that allow drug action and response to be more closely aligned with the clinical situation. Therefore, the platform is able to provide more accurate and reliable data support in drug screening and clinical treatment.
In addition to the above features, the InnoModels Biotechnology ADCC platform also has the advantage of drug response and clinical relevance. The platform is not only applicable to the screening of subject drugs and models, but also capable of predicting the clinical efficacy of drugs. By comparing the subject drug with counterpart drugs (e.g., drugs with similar mechanism of action or standardized therapeutic drugs), the platform can predict the clinical value of the drug, providing a powerful reference for drug development and clinical application.
In addition, the InnoModels Biotechnology ADCC platform has multi-dimensional applications. In addition to drug screening, the platform can also play a role in multiple dimensions. For example, by comparing the efficiency of different cancer type models, the indication of a drug can be determined; by comparing the difference in gene characteristics between sensitive and resistant models, biomarkers that can predict drug efficacy can be searched. This multi-dimensional application makes the platform more widely applicable and can meet the needs of researchers in different fields.
In summary, with its diversified experimental service system, simulation of in vivo environment, highly consistent primary cells, and the advantages of drug efficacy response and clinical relevance, the InnoModels ADCC platform provides powerful support for drug discovery and clinical treatment. With the continuous development of biotechnology, it is believed that the InnoModels Biotechnology ADCC platform will play an even more important role in the future and promote greater breakthroughs and progress in the field of biotechnology.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司